Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment-Reference-Cited by-同舟云学术

Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment

Published:2017-06-19 Issue:4 Volume:121 Page:309-315
ISSN:1742-7835
Container-title:Basic & Clinical Pharmacology & Toxicology
language:en
Short-container-title:Basic Clin Pharmacol Toxicol

Author:

Parra-Guillen Zinnia P.¹²,Berger Peter B.³,Haschke Manuel³,Donzelli Massimiliano³⁴,Winogradova Daria³,Pfister Bogumila⁵,Früh Martin⁵,Gillessen Silke⁵,Krähenbühl Stephan³,Kloft Charlotte¹,Joerger Markus⁵

Affiliation:

1. Department of Clinical Pharmacy and Biochemistry; Institute of Pharmacy; Freie Universitaet Berlin; Berlin Germany

2. Department of Pharmacy and Pharmaceutical Technology; Universidad de Navarra; Navarra Spain

3. Division of Clinical Pharmacology & Toxicology; Department of Biomedicine University Hospital Basel; University of Basel; Basel Switzerland

4. Roche Pharma AG; Basel Switzerland

5. Department of Medical Oncology and Hematology; Cantonal Hospital St. Gallen; St. Gallen Switzerland

Funder

Eastern Switzerland Foundation for Clinical Cancer Research

Roche Pharma AG Basel (Switzerland)

Publisher

Wiley

Subject

Pharmacology,Toxicology,General Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bcpt.12801/fullpdf

Reference27 articles.

1. Erlotinib in previously treated non-small-cell lung cancer;Shepherd;N Engl J Med,2005

2. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial;Rosell;Lancet Oncol,2012

3. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study;Zhou;Lancet Oncol,2011

4. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

5. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Quantitative modeling of tumor dynamics and development of drug resistance in non‐small cell lung cancer patients treated with erlotinib;CPT: Pharmacometrics & Systems Pharmacology;2024-02-20

2. Measurement of CYP1A2 and CYP3A4 activity by a simplified Geneva cocktail approach in a cohort of free-living individuals: a pilot study;Frontiers in Pharmacology;2024-02-02

3. Novel Approaches to Characterize Individual Drug Metabolism and Advance Precision Medicine;Drug Metabolism and Disposition;2023-07-07

4. Genetic Polymorphisms in CYP2C19 Cause Changes in Plasma Levels and Adverse Reactions to Anlotinib in Chinese Patients With Lung Cancer;Frontiers in Pharmacology;2022-06-22

5. Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6‐hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots;Clinical and Translational Science;2022-03-26